Abstract:This is a very large series of PAC placement with an ultrasound-guided approach for left subclavian vein and X-ray confirmation, performed by a single surgeon, demonstrating both the safety and effectiveness of the procedure.
“…In the recent DeliVery for PAH trial (n = 60) intraoperative and perioperative AEs associated with CVC implantation occurred at low rates similar to those observed in our study: the authors reported one case of pneumothorax and three catheter dislocations (all within 1 month of implantation) [16]. In other therapy areas (mainly oncology), intraoperative and perioperative complications associated with CVC implantation have included pneumothorax, accidental arterial puncture, hematoma, dislocations, thrombosis and arrhythmia, and these have varied depending on the implantation protocol [22,23].…”
Section: Discussionsupporting
confidence: 77%
“…Repositioning of the catheter led to complete and durable resolution of the arrhythmia. In previous studies, implantation of CVCs or ports led to arrhythmia in 0.2-13.9% of cases; as in our study, repositioning of the catheters caused the arrhythmias to resolve [22,29]. One case of arrhythmia was reported in the DeliVery for PAH trial; however, this occurred before catheter insertion and was resolved by cardioversion [16].…”
This study supports use of a fully implantable treprostinil infusion pump in patients with PAH requiring parenteral prostanoids. Refills should be performed by specialized healthcare professionals at patients' homes or at experienced centers using approved equipment.
“…In the recent DeliVery for PAH trial (n = 60) intraoperative and perioperative AEs associated with CVC implantation occurred at low rates similar to those observed in our study: the authors reported one case of pneumothorax and three catheter dislocations (all within 1 month of implantation) [16]. In other therapy areas (mainly oncology), intraoperative and perioperative complications associated with CVC implantation have included pneumothorax, accidental arterial puncture, hematoma, dislocations, thrombosis and arrhythmia, and these have varied depending on the implantation protocol [22,23].…”
Section: Discussionsupporting
confidence: 77%
“…Repositioning of the catheter led to complete and durable resolution of the arrhythmia. In previous studies, implantation of CVCs or ports led to arrhythmia in 0.2-13.9% of cases; as in our study, repositioning of the catheters caused the arrhythmias to resolve [22,29]. One case of arrhythmia was reported in the DeliVery for PAH trial; however, this occurred before catheter insertion and was resolved by cardioversion [16].…”
This study supports use of a fully implantable treprostinil infusion pump in patients with PAH requiring parenteral prostanoids. Refills should be performed by specialized healthcare professionals at patients' homes or at experienced centers using approved equipment.
“…However, establishing a method that avoids both complications and technical failure is a challenge. Existing approaches are associated with both complications and technical failure, even with real-time ultrasound guidance or cephalic vein cut-down [3][4][5][6][7][8][9][10][11][12][13][14][15][16].…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, patients who need TIVADs are already in a fragile state. However, the most common approaches, such as percutaneous puncture methods of the subclavian vein (SCV) or the internal jugular vein (IJV), have the risk of causing serious complications, such as pneumothorax, hemothorax, major nerve injury, catheter pinch-off, or catheter kinking [3][4][5][6][7][8][9][10][11]. The cephalic vein (CV) cut-down technique has been recognized as the safest method and is recently being used more frequently [3,6,12], but, unfortunately, this technique is reported to have a high failure rate (6-30%) [5,[12][13][14][15][16].…”
Background
Totally implantable venous access ports (TIVAPs) for chemotherapy are associated with venous thromboembolism (VTE). We aimed to quantify the incidence of TIVAP‐associated VTE and compare it with external central venous catheters (CVCs) in cancer patients through a meta‐analysis.
Methods
Studies reporting on VTE risk associated with TIVAP were retrieved from medical literature databases. In publications without a comparison group, the pooled incidence of TIVAP‐related VTE was calculated. For studies comparing TIVAPs with external CVCs, odds ratios (ORs) were calculated to assess the risk of VTE.
Results
In total, 80 studies (11 with a comparison group and 69 without) including 39 148 patients were retrieved. In the noncomparison studies, the overall symptomatic VTE incidence was 2.76% (95% confidence interval [CI]: 2.24‐3.28), and 0.08 (95 CI: 0.06‐0.10) per 1000 catheter‐days. This risk was highest when TIVAPs were inserted via the upper‐extremity vein (3.54%, 95% CI: 2.94‐4.76). Our meta‐analysis of the case‐control studies showed that TIVAPs were associated with a decreased risk of VTE compared with peripherally inserted central catheters (OR = 0.20, 95% CI: 0.09‐0.43), and a trend for lower VTE risk compared with Hickman catheters (OR = 0.75, 95% CI: 0.37‐1.50). Meta‐regression models suggested that regional difference may significantly impact on the incidence of VTE associated with TIVAPs.
Conclusions
Current evidence suggests that the cancer patients with TIVAP are less likely to develop VTE compared with external CVCs. This should be considered when choosing the indwelling intravenous device for chemotherapy. However, more attention should be paid when choosing upper‐extremity veins as the insertion site.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.